Last reviewed · How we verify
Grace Therapeutics Inc. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
4 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| CaPre | CaPre | marketed | cholestyramine | Cardiovascular | ||
| GTX-104 | GTX-104 | phase 3 | Immune checkpoint inhibitor | PD-1 | Oncology |
Therapeutic area mix
- Cardiovascular · 1
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Brenda Cooper, MD · 1 shared drug class
- Bristol-Myers Squibb · 1 shared drug class
- EMS · 1 shared drug class
- GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
- Glycotope GmbH · 1 shared drug class
- HK inno.N Corporation · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Grace Therapeutics Inc.:
- Grace Therapeutics Inc. pipeline updates — RSS
- Grace Therapeutics Inc. pipeline updates — Atom
- Grace Therapeutics Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Grace Therapeutics Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/grace-therapeutics-inc. Accessed 2026-05-16.